{"id":"NCT00439725","sponsor":"Bayer","briefTitle":"Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study","officialTitle":"Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2009-08","completion":"2009-09","firstPosted":"2007-02-26","resultsPosted":"2012-04-12","lastUpdate":"2014-11-04"},"enrollment":1197,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Venous Thromboembolism"],"interventions":[{"type":"DRUG","name":"Rivaroxaban (Xarelto, BAY59-7939)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rivaroxaban (Xarelto, BAY59-7939)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled, event-driven, superiority study for efficacy. Patients with confirmed symptomatic DVT (deep vein thrombosis) or PE (pulmonary embolism) who completed 6 or 12 months of treatment with rivaroxaban or VKA (vitamin K antagonist) are eligible for this trial (Einstein-Extension study).","primaryOutcome":{"measure":"Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment","timeFrame":"6- or 12-month study treatment period","effectByArm":[{"arm":"Rivaroxaban (Xarelto, BAY59-7939)","deltaMin":1.3,"sd":null},{"arm":"Placebo","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":322,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","Denmark","Finland","France","Germany","Hong Kong","Hungary","India","Indonesia","Israel","Italy","Malaysia","Netherlands","New Zealand","Norway","Philippines","Poland","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["22371186","21128814","40163217","38844941","27262225","25698905"],"seeAlso":["http://www.nhlbi.nih.gov/health/health-topics/topics/dvt/","http://www.nhlbi.nih.gov/health/health-topics/topics/pe/","http://www.clinicaltrialsregister.eu"]},"adverseEventsSummary":{"seriousAny":{"events":59,"n":598},"commonTop":["Pain in extremity","Nasopharyngitis"]}}